FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2578893998> ?p ?o ?g. }

• W2578893998 endingPage "4828" @default.
• W2578893998 startingPage "4828" @default.
• W2578893998 abstract "Abstract Changes in circulating levels of biomarkers of cell death (such as nucleosomal DNA, nDNA) within days of starting chemotherapy are highly predictive of end of treatment response rates and progression-free survival in acute myeloid leukaemia, lung and bowel cancers1–3. In aggressive lymphoma, depth of response as measured by computed tomography (CT) at the end of treatment is a useful predictor of long-term survival4. If early blood-borne biomarker data were predictive of end of treatment response in lymphoma, this may provide an opportunity to make timely changes to treatment. Thus the aims of this study were to measure circulating nDNA before and during chemotherapy for lymphoma, to correlate biomarker changes in blood levels with those in one and two dimensional (1, 2D) tumor measurements by CT and to evaluate the sensitivity of blood-borne nDNA and imaging biomarkers for predicting treatment response. Serum samples from 17 patients with lymphoma (8 Hodgkin (HL) and 9 Non Hodgkin (NHL) cases) treated with standard chemotherapy were analysed for nDNA using the cell death detection kit™ (Roche) according to manufacturers’ instructions. Serial samples were taken pre-treatment (day 1 baseline) and on days 3, 8 and 15 of the first chemotherapy cycle. Control samples were taken from a healthy volunteer panel. Baseline and end of therapy CT images were obtained using a LightSpeed Plus CT scanner with typical helical acquisition parameters. Data were acquired following intravenous contrast and images were reformatted to contiguous non-overlapping 5mm slices to allow future calculation of tumor volume. One and 2D measurements of tumor size were determined by a radiologist blinded to nDNA data. Levels of nDNA were significantly higher in all lymphoma subtypes compared with 61 healthy controls (median 1.4 vs 0.3, p&lt;0.005), but showed no relationship with absolute pre- or post-treatment tumor dimensions. Neither LDH nor prognostic score (international prognostic indices for NHL and Hasenclever score for HL) predicted end of treatment tumor dimensions or treatment induced change in tumor dimensions. In contrast, dramatic falls in nDNA levels were observed within the first week after chemotherapy (p=0.02) and both baseline and day 8 nDNA levels correlated well with proportional end of treatment tumor shrinkage assessed by 2D measurements (R=0.6, p=0.01 and R=0.64, p=0.005, respectively). Corresponding area under the ROC curve values for 80% reduction at end of therapy (shown below) were 0.81 and 0.8 (P=0.04) each for baseline and day 8 nDNA levels, equating to a specificity of 80% and sensitivity of 71.5%. These data identify baseline and day 8 post-treatment nDNA as sensitive predictive biomarkers of end of treatment response in lymphoma, which warrants further investigation. Early phase clinical trials incorporating circulating nDNA are underway to begin to qualify circulating nDNA as a predictor of progression free and overall survival, and to compare nDNA with 1, 2 and 3D CT measurements as a potentially powerful multimodality biomarker approach. Figure Figure Figure illustrating that Receiver Operating Characteristics for nDNA are significantly superior to baseline LDH in terms of predicting tumor shrinkage of 80% or more at end of therapy (dashed line where test is equivalent to chance)" @default.
• W2578893998 created "2017-01-26" @default.
• W2578893998 creator A5011398209 @default.
• W2578893998 creator A5013301618 @default.
• W2578893998 creator A5015988282 @default.
• W2578893998 creator A5018478201 @default.
• W2578893998 creator A5027381315 @default.
• W2578893998 creator A5028246201 @default.
• W2578893998 creator A5030144131 @default.
• W2578893998 creator A5032280351 @default.
• W2578893998 creator A5055792960 @default.
• W2578893998 creator A5058954518 @default.
• W2578893998 creator A5069625387 @default.
• W2578893998 creator A5076384970 @default.
• W2578893998 creator A5091801564 @default.
• W2578893998 date "2008-11-16" @default.
• W2578893998 modified "2023-09-26" @default.
• W2578893998 title "A Blood Borne Biomarker of Cell Death (nucleosomal DNA) Is An Early Predictor of End of Treatment Response to Chemotherapy in Lymphoma" @default.
• W2578893998 cites W1752162629 @default.
• W2578893998 cites W2125629118 @default.
• W2578893998 doi "https://doi.org/10.1182/blood.v112.11.4828.4828" @default.
• W2578893998 hasPublicationYear "2008" @default.
• W2578893998 type Work @default.
• W2578893998 sameAs 2578893998 @default.
• W2578893998 citedByCount "0" @default.
• W2578893998 crossrefType "journal-article" @default.
• W2578893998 hasAuthorship W2578893998A5011398209 @default.
• W2578893998 hasAuthorship W2578893998A5013301618 @default.
• W2578893998 hasAuthorship W2578893998A5015988282 @default.
• W2578893998 hasAuthorship W2578893998A5018478201 @default.
• W2578893998 hasAuthorship W2578893998A5027381315 @default.
• W2578893998 hasAuthorship W2578893998A5028246201 @default.
• W2578893998 hasAuthorship W2578893998A5030144131 @default.
• W2578893998 hasAuthorship W2578893998A5032280351 @default.
• W2578893998 hasAuthorship W2578893998A5055792960 @default.
• W2578893998 hasAuthorship W2578893998A5058954518 @default.
• W2578893998 hasAuthorship W2578893998A5069625387 @default.
• W2578893998 hasAuthorship W2578893998A5076384970 @default.
• W2578893998 hasAuthorship W2578893998A5091801564 @default.
• W2578893998 hasBestOaLocation W25788939982 @default.
• W2578893998 hasConcept C126322002 @default.
• W2578893998 hasConcept C126838900 @default.
• W2578893998 hasConcept C142724271 @default.
• W2578893998 hasConcept C143998085 @default.
• W2578893998 hasConcept C2776256026 @default.
• W2578893998 hasConcept C2776611710 @default.
• W2578893998 hasConcept C2776694085 @default.
• W2578893998 hasConcept C2778336483 @default.
• W2578893998 hasConcept C2779338263 @default.
• W2578893998 hasConcept C2781197716 @default.
• W2578893998 hasConcept C55493867 @default.
• W2578893998 hasConcept C71924100 @default.
• W2578893998 hasConcept C86803240 @default.
• W2578893998 hasConceptScore W2578893998C126322002 @default.
• W2578893998 hasConceptScore W2578893998C126838900 @default.
• W2578893998 hasConceptScore W2578893998C142724271 @default.
• W2578893998 hasConceptScore W2578893998C143998085 @default.
• W2578893998 hasConceptScore W2578893998C2776256026 @default.
• W2578893998 hasConceptScore W2578893998C2776611710 @default.
• W2578893998 hasConceptScore W2578893998C2776694085 @default.
• W2578893998 hasConceptScore W2578893998C2778336483 @default.
• W2578893998 hasConceptScore W2578893998C2779338263 @default.
• W2578893998 hasConceptScore W2578893998C2781197716 @default.
• W2578893998 hasConceptScore W2578893998C55493867 @default.
• W2578893998 hasConceptScore W2578893998C71924100 @default.
• W2578893998 hasConceptScore W2578893998C86803240 @default.
• W2578893998 hasIssue "11" @default.
• W2578893998 hasLocation W25788939981 @default.
• W2578893998 hasLocation W25788939982 @default.
• W2578893998 hasOpenAccess W2578893998 @default.
• W2578893998 hasPrimaryLocation W25788939981 @default.
• W2578893998 hasRelatedWork W2008455091 @default.
• W2578893998 hasRelatedWork W2276858584 @default.
• W2578893998 hasRelatedWork W2295588572 @default.
• W2578893998 hasRelatedWork W2358450743 @default.
• W2578893998 hasRelatedWork W2381460883 @default.
• W2578893998 hasRelatedWork W2398215928 @default.
• W2578893998 hasRelatedWork W2413020017 @default.
• W2578893998 hasRelatedWork W2480785262 @default.
• W2578893998 hasRelatedWork W3029538681 @default.
• W2578893998 hasRelatedWork W3088489528 @default.
• W2578893998 hasVolume "112" @default.
• W2578893998 isParatext "false" @default.
• W2578893998 isRetracted "false" @default.
• W2578893998 magId "2578893998" @default.
• W2578893998 workType "article" @default.